Analyst Reco. Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:24 2024-04-18 am EDT			5-day change	1st Jan Change
4,978 ^ILa	+0.57%		-4.47%	+30.48%

Apr. 17	Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	CI
Apr. 16	Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	Mar. 08	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	Feb. 12	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	Feb. 05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	Feb. 05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	Jan. 29	MT
Teva: share price up, broker in support	Jan. 23	CF
TEVA : Jefferies raises its recommendation	Jan. 23	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	Jan. 23	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	Jan. 12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	Jan. 03	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	Dec. 18	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	Nov. 27	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	23-07-06	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	23-05-18	MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating	23-02-09	MT
Jefferies Downgrades Teva Pharmaceutical Industries to Hold From Buy, Adjusts Price Target to $12 From $10	23-01-19	MT
UBS Downgrades Teva Pharmaceutical Industries to Sell From Neutral, Adjusts Price Target to $7 From $10	22-11-04	MT
Jefferies Assumes Teva Pharmaceutical Industries at Buy with $10 Price Target	22-10-21	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $11 From $13, Maintains Buy Rating	22-10-14	MT
BofA Securities Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $10	22-08-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT